PCH
SNDX icon

Polar Capital Holdings’s Syndax Pharmaceuticals SNDX Stock Holding History

Polar Capital Holdings’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500,000
Closed -$6.61M – 315
2024
Q4 		$6.61M Hold
500,000
– – 0.04% 238
2024
Q3 		$9.63M Buy
+500,000
New +$10.3M 0.05% 206

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Polar Capital Holdings's SNDX Position: Q1 2025 in Review

Polar Capital Holdings sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 500,000 shares — an estimated $6.61M sold.

Polar Capital Holdings first reported a position in SNDX in Q3 2024 and held it in 2 quarters. The position peaked at $9.63M in Q3 2024. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

  • Polar Capital Holdings reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Polar Capital Holdings sold 500,000 Syndax Pharmaceuticals shares in Q1 2025, an estimated $6.61M.
  • Polar Capital Holdings first reported a position in Syndax Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Polar Capital Holdings's Syndax Pharmaceuticals position peaked at $9.63M in Q3 2024.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Polar Capital Holdings's 13F filing for Q1 2025, filed 15 May 2025.